Coherus Oncology, Inc.
No SEC Form 4 filings for $CHRS in the last 30 days.
See all $CHRS insider activity →Coherus Oncology, Inc. (CHRS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 chrs-20260817xex10d1.htm EX-10.1 Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this
Coherus Oncology (CHRS) reported Q2 2026 results on an earnings call. LOQTORZI net revenue was $13.6M, up 15% sequentially and 37% YoY. Full-year LOQTORZI guidance is $57M to $62M. Total net revenue from continuing ops was $14.3M. Cash and marketable securities were $105.3M at June 30, 2026.
Coherus Oncology (NASDAQ:CHRS) reported Q2 updates on tagmokitug and LOQTORZI during an earnings call. It said preliminary head and neck response and biomarker findings are based on limited patients, with formal disclosure expected in October. LOQTORZI net sales were $13.6M, up 15% sequentially. Full-year 2026 LOQTORZI revenue guidance is $57M to $62M; 2026 operating expenses $170M to $175M.
Over the past 7 days, alphai's AI scored 2 news stories mentioning CHRS (Coherus Oncology, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent CHRS coverage spans financial news, earnings and corporate actions.
The 8-K discloses a new secured borrowing framework, which can tighten liquidity and increase default sensitivity via covenants and collateral terms.
The call provides fresh operating and clinical-readout inputs that can reprice CHRS expectations for 2026 revenue trajectory and near-term catalyst timing.
Near-term trading focus is on LOQTORZI demand trajectory and cost/cash runway, plus multiple oncology readouts scheduled for late 2026.
The filing provides fresh quarterly financial datapoints plus forward-looking clinical readout timing, which can move near-term sentiment and positioning.
Trial initiation and dosing plan can shift perceived clinical probability for LOQTORZI expansion and ZM008’s NK/LLT1 checkpoint approach.
alphai scores every news story that mentions CHRS with an AI model for sentiment and relevance, and aggregates insider trades from Coherus Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Coherus Oncology, Inc. (CHRS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 chrs-20260817xex10d1.htm EX-10.1 Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this
6 min readCoherus Oncology (CHRS) reported Q2 2026 results on an earnings call. LOQTORZI net revenue was $13.6M, up 15% sequentially and 37% YoY. Full-year LOQTORZI guidance is $57M to $62M. Total net revenue from continuing ops was $14.3M. Cash and marketable securities were $105.3M at June 30, 2026.
6 min readCoherus Oncology (NASDAQ:CHRS) reported Q2 updates on tagmokitug and LOQTORZI during an earnings call. It said preliminary head and neck response and biomarker findings are based on limited patients, with formal disclosure expected in October. LOQTORZI net sales were $13.6M, up 15% sequentially. Full-year 2026 LOQTORZI revenue guidance is $57M to $62M; 2026 operating expenses $170M to $175M.
6 min readCoherus Oncology, Inc. (CHRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 chrs-20260805xex99d1.htm EX-99.1 Exhibit 99.1 Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update – LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with
6 min readCoherus Oncology and Zumutor Biologics said they will collaborate on a Phase 1 trial combining ZM008, an NK checkpoint anti-LLT1 antibody, with LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor. The study will enroll up to 45 patients in the U.S. across dose-escalation and expansion cohorts for several solid tumors, including CRC, HNSCC, NSCLC, ccRCC and urothelial cancers.
3 min readCoherus Oncology Inc. (NASDAQ: CHRS) is identified as a top penny stock with potential to triple money, following its Q4 2025 earnings report. The company showed progress with increased LOQTORZI sales and significant debt reduction, signaling a transition towards an oncology-focused business. Management anticipates further growth through revenue, partnerships, and clinical catalysts in 2026 for its immunotherapy pipeline.
4 min readDelveInsight's report highlights significant advancements in the Metastatic Hepatocellular Carcinoma (HCC) pipeline, with over 20 companies and 25+ pipeline drugs in development. Key clinical trial updates include Coherus Oncology Inc.'s Phase 2 trial for SRF388 and AstraZeneca's Phase I/II study for AZD5851. The report details several promising emerging drugs like CS1003, Casdozokitug, TTI-101, and ST316, emphasizing the robust research efforts to address this challenging cancer.
3 min readCoherus BioSciences (CHRS) is expected to report a significant decline in EPS and revenue for Q4, with analysts forecasting -$0.31 EPS and $14.09 million in revenue. The biotechnology company, focusing on oncology, shows financial distress indicators like a negative Altman Z-Score and declining revenue growth. Despite the financial challenges, its strategic focus on expanding the oncology pipeline offers potential long-term growth, though near-term risks remain significant.
4 min readCoherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readREDWOOD CITY, Calif., Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- Coherus Oncology, Inc. ( NASDAQ:CHRS ) , today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer ( SITC ) being held November 5-9, 2025, in National Harbor, Maryland.
3 min read
